Stelara Biosimilar Rollouts Begin, but Various Factors Could Tank Their Uptake

Jan 09
Jan 09, 2025

The beginning of the new year is seeing the start of the next wave of highly anticipated biosimilars: those of Stelara (ustekinumab) from Johnson & Johnson Innovative Medicine (formerly Janssen Biotech, Inc.), kicked off by Amgen Inc.’s Wezlana (ustekinumab-auub) on Jan. 1. As seen in the launches of multiple biosimilars of AbbVie Inc.’s Humira (adalimumab), multiple factors may impact the agents’ uptake, say industry experts.

Stelara is approved for the treatment of adults and pediatric patients at least 6 years old with moderate-to-severe plaque psoriasis who are candidates for phototherapy or systemic therapy, adults and pediatric patients at least 6 years old with active psoriatic arthritis, adults with moderately to severely active Crohn’s disease and adults with moderately to severely active ulcerative colitis.
Read more
© 2025 MMIT

Angela Maas

Angela has an extensive background of editing, reporting and writing for trade and consumer publications. She has written Radar on Specialty Pharmacy since she joined AIS Health in 2005 and has broad knowledge of the various issues at play within the space. She also has written for Spotlight on Market Access since its 2017 launch. Before joining AIS Health, she was managing editor at Employee Benefit News and Employee Benefit News Canada and managing editor at Hem Aware (a hemophilia publication), Lupus Living and Momentum (a multiple sclerosis publication). She has a B.A. in English and an M.A. in British literature from Arizona State University.